Respiratory Tract Infection Treatment Market to Experience Significant Growth with a CAGR of 6.8 %and Reach a Value of U

Comentarios · 131 Puntos de vista

nikita gawade 18 Jul 2023

Respiratory Tract Infection Treatment Market By Drug Class (Cough Suppressant, Nasal Decongestant, Antibiotics, Non-Steroidal Anti-Inflammatory Drug (NSAIDS), and Others), By Disease Indication (Upper Respiratory Tract Infection and Lower Respiratory Tract Infection), by Distribution Chann

Sample link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/136

Key Highlights:

· In October 2021, Dr. Michael Ison of Northwestern University and Dr. Jolan Walter of the University of So Paulo will present an exclusive educational event on respiratory viral infections at IDWeek 2021, hosted by ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics.

· In October 2021, The Johnson & Johnson subsidiary Janssen Pharmaceutical Companies announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against RSV-related lower respiratory tract disease (LRTD), with vaccine efficacy of 80 percent (CI, 52.2-92.9 percent) in adults aged 65 and older.

#Respiratory Tract Infection Treatment Market trends